CJC-1295 (no DAC)
Modified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
FDA Status
Not FDA-approved — Category 1 (compounding allowed)
Typical Dose
100–300 mcg before bed (subcutaneous)
Evidence Grade
BLimited clinical + robust preclinical evidence
Clinics Indexed
156 providers have offered CJC-1295 (no DAC) in our tracked directory.
Key Reported Benefits
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 1 (compounding allowed)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
Related Peptides
Ipamorelin
BA selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
BPC-157
B+A 15-amino-acid peptide derived from gastric juice. The most popular recovery peptide with 100+ preclinical studies showing accelerated healing of tendons, ligaments, muscle, gut lining, and nerves.
TB-500
BA synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
GHK-Cu
B+A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes. The most studied peptide for skin rejuvenation with both preclinical and clinical topical evidence.